Whether it was a mistake as FDA indicated or a trial balloon that quickly burst, the agency generated substantial buzz over its short-lived idea to require that biosimilar sponsors propose 10 potential nonproprietary name suffixes.
Concerns may have arisen in part because of the work and cost that could be involved in selecting the random...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?